Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients

REFERENCES

• Lennox J, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet. 2009;374:796–806.
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417)1253–1263.
   Web of Science ®Google Scholar
• Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment naïve HIV-1 infected patients. Antivir Ther. 201116: 759–769.
   Google Scholar
• Cohen C, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two nucleoside or nucleotide reverse transcriptase inhibitors in treatment naive adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial. Lancet. 2011;378:229–237.
   PubMed Web of Science ®Google Scholar
• Molina J, Cahn P, Grinszstein B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011378: 229–237.
   Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS. 2009;23:2289–2300.
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1 infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15:1045–1052.
   PubMed Web of Science ®Google Scholar
• Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(12):4680–4866.
   PubMed Web of Science ®Google Scholar
• Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47(10):2550–2560.
   PubMed Web of Science ®Google Scholar
• Gruzdev B, Rakhamanova A, Doubovaskaya E, et al. A randomized, double-blind, placebo controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve, HIV-1 infected subjects. AIDS. 2003;17:2487–2494.
   PubMed Web of Science ®Google Scholar
• Scholler-GyOre M, Kakuda TN, Raoof A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561–574.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Lalezari J, Osiyemi 0, Puane P, Kakuda T, Witek J. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in anti-retroviral-naïve HIV type-1 infected adults. Antivir Ther. 2010;15:711–720.
   PubMed Web of Science ®Google Scholar
• Schneider L, Ktorza N, Fourati S, Assoumou L, Courbon E, Caby F. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: The Monetra Study. HIV Clin Trials. 2012;13:284–288.
   PubMed Web of Science ®Google Scholar
• Nelson M, Stellbrink H, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 2011;25(3):335–340.
   PubMed Web of Science ®Google Scholar
• Gazzard B, Duvivier C, Zagler C, et al. Phase 2 double-blind, randomized trial of etravirine versus efavi-renz in treatment-naïve patients: 48-week results. AIDS. 2011;25(18):2249–2258.
   PubMed Web of Science ®Google Scholar
• DAIDS 2004. Division of AIDS table for grading the severity of adult and paediatric adverse events. http://www.rsc.tech-res.com/safetyandpharmacovigilance/. Accessed April 2011.
   Google Scholar
• Kakuda TN, Schöller-Gyüre M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic inter-action between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med. 2009;10:173–181.
   PubMed Web of Science ®Google Scholar
• Kakuda T, Wade J, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced patients. Clin Pharmacol Ther. 2010;88:695–703.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(9):1192–1194.
   PubMed Web of Science ®Google Scholar
• Hill A, Sabin C. Designing and interpreting HIV nonin-feriority trials in naive and experienced patients. AIDS. 2008;22:913–921.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Valencia A, Lopez-Cortes L, Vicana P, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med. 2009;151(3):149–156.
   PubMed Web of Science ®Google Scholar